

Ticker: RBW LN Net cash: £8.5m Project: Phalaborwa Market cap: £89m **Price:** £0.175/sh Country: South Africa

RECOMMENDATION (unc): BUY TARGET: £0.35/sh (unc) RISK RATING: HIGH

We see three key takeaways from today's detailed metallurgical and processing update from Rainbow. First, the key advantages of the operation are strongly supported test work, namely low acid consumption at 110g/L, good recoveries at 66% leach recovery at 40°C leach, short leach time at 12h and suitable for sulphuric acid lixiviant. As Phalaborwa has sulphuric acid available from the nearby PMC copper smelter and power and rail to site, these confirm that Phalaborwa's location and infrastructure can be leveraged to reduce opex and capex. **Second**, the initial K-tech desktop study indicates ability to produce 99.5-99.9% purity separated rare earth oxides, allowing Rainbow to capture greater value (90-100% pay-ability of benchmark oxide prices) compared to a mixed REO carbonate (60-65% pay-ability). Third, the detailed test work supports what is a key advantage for Rainbow in our view: an experienced mine-building team and structured approach to development. We can't overstate the importance of this. Rainbow's team have extensive processing plant and tailings plant building experience and the detailed design and test work, lab pilot and site pilot stages being implemented combined with low capex give us great confidence that Phalaborwa is an excellent risk-weighted upside opportunity to play the magnet rare earths thematic.

Model changes: Highlighted in greater detail below but we lift our LT NdPr price to US\$100/kg, still well below current prices, and adjust our recovery assumptions to 60% from 70%, in line with conservative interpretations of the test work. We maintain our BUY rating and 35p/sh price target based on 0.5x NAV_{8%-100/kg}. Stepping back, we believe that Rainbow the best risk adjusted return profile of any NdPr developer due to location, infrastructure in place, the already treated nature of the mineralization, and Rainbow's experienced plant-building management team.

Detailed met release confirms recovery, low acid consumption, short leach time

Rainbow released a detailed update on metallurgical and processing design and study work led by ANSTO in Sydney, Australia. Key outcomes included confirmation of suitability of sulphuric acid as lixiviant, optimised leach recovery (average 66% rare earth leach recovery) at 40°C at 12-hr residence, sulphuric acid concentration of 110-150g/L in the leach (subject to further optimisation). Nano filtration desktop study indicated 65% sulphuric acid recovery for recycling and 99% rare earth recovery to concentrate, with a 3x concentration factor. Rare earth separation desktop study by K-Tech indicated potential to produce separated rare earth oxides at 99.5-99.9% purity using K-Tech continuous chromatography and continuous ion exchange technology. Further optimisations include reducing PLS volume (through tenor increase) to rare earth separation to reduce capex and opex, optimisation of rare earth separation recovery (80% assumed in desktop study), pre-leach impurity control (notably of fluoride)




Figure 1: (A) Temperate effect and residence time curve, (B) acid concentration and REE recovery

Source: Rainbow Rare Earths

Our view and model updates: Excellent

Overall, we are very impressed with the detail and quality of the test work. It goes well beyond the requirements for the upcoming scoping study and reflects well on management's experience building processing facilities. With regard to process and design, the key advantages of the project were supported by test work and overall scope is in line with our site visit takeaways, namely a hydro slurry operation feeling a sulphuric acid leach circuit with potential to produce separated rare earth oxides. The temperature and acid consumption.

Model changes:

We make two principal changes.

- 1) We update our LT price estimate to US\$100kg/t for benchmark NdPr oxide (FOB). We maintain our 90% pay-ability of benchmark separated oxide prices assumption. We think higher pay-ability is certainly achievable if Rainbow is able to achieve 99.5-99.9% purity, particularly as we think material produced outside of China by western companies may receive a premium due to end user diversification initiatives and current geopolitical realities.
- 2) We amend our recovery assumptions to 60% to separated oxides based on the 66% average leach recovery and a ~90% assumed separation recovery (subject to more test work). In our view a 60-65% overall recovery to separated oxides is achievable on further optimisation assuming 65-70% leach recovery and 90-95% separation recovery.

For now, we maintain our 2.2Mtpa throughput assumption but note that higher throughput (and therefore production rates) may be achieved in our view, particularly if optimisation work is able to achieve higher solution tenors to concentrate, which would enable either cost savings (a smaller footprint and operation) or higher production rates in the separation phase (maintain facility size, achieve more production).

We reiterate our BUY rating and £0.35/sh price target based on 0.5xNAV8%. While today's changes result in moderately lower production, we think the quality of test work, the fact that we are running prices well below spot, and the conservative 0.5x NAV multiple are all indicative of Rainbow's excellent risk-adjusted upside. At US\$100/kg, we estimate that Rainbow is trading at just 0.12x NAV8% with a 45% Phalaborwa project IRR, which is an excellent return on a brownfield project in a mature mining jurisdiction with access to good infrastructure that is one of few projects globally that can contribute magnet rare earths to the western supply chain by 2025.

Why we like Rainbow Rare Earths

- Tailings project located on existing industrial facility results in low capex and opex
- 2. High per tonne value due to NdPr, Dy, Tb assemblage and ability to produce beneficiated product
- 3. Proven management team that has built numerous mines and tailings projects

Catalysts

- 1H22: PEA
- 2H22: DFS and parallel lab testing.
- 2023: Pilot plant (H1), mid-year construction decision
- 2024: SCPe ramp up, commercial production in 2025

Research

Justin Chan (London) M: +44 7554 784 688 jchan@sprott.com
Brock Salier (London) M: +44 7400 666 913 bsalier@sprott.com
Brandon Gaspar (Toronto) M: +1 437 533 3142 bgaspar@sprott.com

Eleanor Magdzinski (Toronto) M: +1 705 669 7456 emagdzinski@sprott.com

Sprott Capital Partners

	Price / mkt cap: Rec / PT:	£0.17/sh, £89m BUY / £0.35				Market P/NAV: 1xNAV _{2Q20} FD:	0.13x US\$0.96/sh		Assets: Country:	Phalaborwa South Africa	
Group-level SOTP valuation	4021	1Q22e				Resource / Reserve	Mt	% TREO	000t REO	000t NdPr	
Group-level 30 1P valuation	4Q21	US\$m	O/ship	NAVx	£/sh	Measured, ind. & inf.	38	0.43%	165	48	1,221
Phalaborwa NPV 1Q22e		537	80%	0.50x	0.69	SCPe Mine Inventory	38	0.43%	163	48	1,235
Central SG&A & fin costs 1Q22e		(122)	-	0.50x	(0.12)	Commodity price	Jun '22	Jun '23	Jun '24	Jun '25	Jun '26
Tonnes outside mine plan (5% insitu va	duo)	2	100%	0.50x	0.00	NdPr price (US\$/t)	83	83	100	100	100
<u> </u>	ilue)	11	100%		0.00		03	03	100	100	100
Cash and restr. cash 4Q21			-	0.50x		Share data	ED.	()	522.0	ED /EE	041.5
Cash from options		1	-	0.50x	0.00	Basic shares (m): 511.8		options (m):	523.0	FD/FF	814.6
Debt 4Q21		(1)	-	0.50x	(0.00)	Ratio analysis	Jun '22	Jun '23	Jun '24	Jun '25	Jun '26
Gakara		75	_	0.50x	0.07	FD shares out (m)	577	782	782	782	782
1xNAV8% spot fully diluted, pre-fund	ed	503			0.66	EPS (US\$/sh)	(0.00)	(0.00)	(0.00)	0.07	0.09
Assumed equity raised to first product	ion	60		0.50x	0.07	CFPS before w/c (US\$/sh)	(0.00)	0.00	(0.02)	0.05	0.11
1xNAV8% spot fully funded		563			0.35	FCFPS pre growth (US\$/sh)	(0.00)	0.03	0.00	0.05	0.11
1x fully funded NAVPS sensitivity to g		count / N/	AV multiple			FCF/sh (US\$/sh)	(0.02)	(0.07)	(80.0)	0.05	0.11
Valuation (£/sh)	\$50/kg	\$75/kg	\$100/kg	\$125/kg	\$150/kg	FCF yield pre growth (US\$/sh)	(2%)	17%	2%	28%	62%
0.25xNAV	0.03	0.10	0.18	0.26	0.34	FCF yield (%)	(9%)	(41%)	(47%)	28%	62%
0.50xNAV	0.04	0.18	0.35	0.51	0.68	EBITDA margin (%)	-	-	42%	68%	69%
0.75xNAV	0.05	0.27	0.51	0.77	1.02	FCF margin (%)			(232%)	25%	41%
1.00xNAV	0.06	0.36	0.68	1.02	1.36	ROA (%)	(7%)	(3%)	(2%)	25%	25%
Phalaborwa NPV8% (US\$m)	\$50/kg	\$75/kg	\$100/kg	\$125/kg	\$150/kg	ROE (%)	(7%)	(5%)	(3%)	42%	35%
12% discount	59	219	378	538	698	ROCE (%)	(7%)	(2%)	7%	51%	58%
10% discount	81	265	449	633	817	PER (x)	(45x)	(33x)	(55x)	3x	2x
8% discount	109	323	537	751	965	P/CF (x)	(50x)	(38x)	(113x)	2x	2x
6% discount	144	395	647	898	1,150	EV/EBITDA (x)	(45x)	(66x)	17x	2x	1x
5% discount	164	438	712	986	1,260	Income statement	Jun '22	Jun '23	Jun '24	Jun '25	Jun '26
Phalaborwa 1xNAV sensitivity to reco	very and payabi	lity				Revenue (US\$m)			28	152	203
Phalaborwa NPV8% (US\$m)	Recov: 55.0%	57.5%	60.0%	62.5%	65.0%	COGS (US\$m)			(12)	(44)	(59)
Payability: 60%	463	500	537	573	610	Gross profit (US\$m)			16	108	144
Payability: 70%	463	500	537	573	610	Expenses (US\$m)	(3)	(4)	(2)	(2)	(2)
Payability: 80%	463	500	537	573	610	Impairment & other (US\$m)					
Payability: 90%	463	500	537	573	610	Net finance costs (US\$m)		(2)	(8)	(8)	(8)
Payability: 100%	463	500	537	573	610	Tax (US\$m)			(5)	(37)	(36)
Valuation over time	Jun '21	Jun '22	Jun '23	Jun '24	Jun '25	Minority interest (US\$m)					(20)
Mines NPV (US\$m)	509.2	554.2	659.4	753.9	725.9	Net income attr. (US\$m)	(3)	(6)	0	61	78
Cntrl G&A & fin costs (US\$m)	(127.8)	(118.1)	(124.8)	(104.0)	(69.7)	EBITDA (US\$m)	(2)	(2)	12	104	140
Gakara & other	77.1	77.1	77.1	77.1	77.1	Cash flow	Jun '22	Jun '23	Jun '24	Jun '25	Jun '26
Net cash at 1Q (A\$m)	7.9	9.2	3.6	(60.8)	(22.5)	Profit/(loss) after tax (US\$m)	(2)	(4)	(2)	52	67
1xNAV (US\$m)	466	522	615	666	711	Add non-cash items (US\$m)			1	7	9
P/NAV (x):	0.20x	0.17x	0.15x	0.14x	0.13x	Less wkg cap / other (US\$m)		4	(12)	(17)	11
1xNAV share px FD (US\$/sh)	0.89	1.00	1.18	1.27	1.36	Cash flow ops (US\$m)	(2)	0	(14)	42	87
•	411%	139%	89%	64%	51%	PP&E (US\$m)	(5)	(56)	(51)	(3)	(3)
ROI to equity holder (% pa) Sources and uses of cash	41176	139%	03%	04 //	31%	Other (US\$m)	(5)	(36)	(51)	(3)	(3)
	UC#40	ccr		h	LIC#42	I					
SCPe evaluation costs	US\$10m US\$100m	SCF	e current cas		US\$12m	Cash flow inv. (US\$m) Debt draw (repayment) (US\$m)	(7)	(56)	(51)	(3)	(3)
SCPe capex				ebt package	US\$80m			40	40		(15)
SCPe contingency	US\$16m		EC	uity Raised	US\$60m	Equity issuance (US\$m)	11	50			
SCPe G&A + fin. cost to first Au	US\$13m					Other (US\$m)					
SCPe working capital	US\$9m					Cash flow fin. (US\$m)	11	90	40		(15)
Total uses	US\$148m		Tot	al proceeds	US\$152m	Net change post forex (US\$m)	1	34	(24)	38	69
*Cash from options expiring pre first pou	ır					FCF (US\$m)	(9)	(56)	(64)	38	84
Production profile						Balance sheet	Jun '22	Jun '23	Jun '24	Jun '25	Jun '26
Production (kt REO) 8.0				Rev / C	ost (US\$/t) — 40,000	Cash (US\$m)	11	45	21	59	128
6.0		_			30,000	Accounts receivable (US\$m)	1	2	4	13	14
4.0					20,000	Inventories (US\$m)	0	3	6	18	6
2.0					10,000	PPE & exploration (US\$m)	18	74	124	120	114
2024 2025 2026 2027 20	28 2029 2030	2031	2032 2033	2034 203	5	Other (US\$m)	0	0	0	0	0
Production (kt Nd+Pr, LHS)	Production (kt, D	y+Tb, LHS)	Produ	ction (kt, other RE	O, LHS)	Total assets (US\$m)	30	124	155	210	262
						Debt (US\$m)	2	42	82	82	67
Production (100%)	Jun '24	Jun '25	Jun '26	Jun '27	Jun '28	Other liabilities (US\$m)	1	9	2	5	5
Phalaborwa (kt TREO)	774	4,257	5,676	5,676	5,676	Shareholders equity (US\$m)	53	103	103	103	103
Phalaborwa (kt Nd+Pr)	225	1,238	1,651	1,651	1,651	Retained earnings (US\$m)	(24)	(28)	(31)	22	88
Phalaborwa cash cost (US\$/t)	14,858	9,690	9,690	9,690	9,690	Minority int. & other (US\$m)	(1)	(1)	(1)	(1)	(1)
Phalaborwa AISC (US\$/t)	19,107	13,526	13,235	13,235	13,235	Liabilities+equity (US\$m)	30	124	155	210	262
Group cash cost (US\$/t)	15,574	10,406	10,406	10,406	10,406	Net cash (US\$m)	9	4	(61)	(23)	62
Group AISC (US\$/t)	20,582	11,876	11,411	11,411	11,411	Net debt to NTM EBITDA (x)	4.6x	(0.3x)	0.6x	0.2x	(0.4x)

Source: SCP estimates

Equity Research

DISCLOSURES & DISCLAIMERS

This research report (as defined in IIROC Rule 3400) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an $investment\ dealer\ who\ is\ a\ member\ of\ the\ Investment\ Industry\ Regulatory\ Organization\ of\ Canada\ ("IIROC")\ and\ th\ e\ Canadian\ Investor\ Protection\ investment\ Alberton and\ Albert$ Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

DISSEMINATION OF RESEARCH: SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact unsubscribe@sprott.com and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

RESEARCH ANALYST CERTIFICATION: Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party
 except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

UK RESIDENTS: Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS: This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.



Equity Research

ANALYST CERTIFICATION / REGULATION AC: The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

SPROTT CAPITAL PARTNERS EXPLANATION OF RECCOMENDATIONS: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market


TENDER: The analyst recommends tendering shares to a formal tender offering

UNDER REVIEW: The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a reevaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED ((N/R): The stock is not currently rated

Re	Research Disclosure					
1	SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities ¹					
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO				
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO				
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	YES				
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO				
6	SCP is making a market in an equity or equity related security of the issuer	NO				
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO				
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	YES				
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO				

Sprott Capital Partners Equity Research Ratings:



¹ As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month



Page 5